×

Composition and method for the diagnosis and treatment of iron-related disorders

  • US 9,636,398 B2
  • Filed: 12/13/2012
  • Issued: 05/02/2017
  • Est. Priority Date: 12/14/2011
  • Status: Active Grant
First Claim
Patent Images

1. An isolated antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a domain or region selected from the group consisting of:

  • (a) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;

    43, (b) a variable light domain region comprising the amino acid sequence of SEQ ID NO;

    47, (c) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;

    51, (d) a variable light domain region comprising the amino acid sequence of SEQ ID NO;

    55, (e) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;

    59, (f) a variable light domain region comprising the amino acid sequence of SEQ ID NO;

    63, (g) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;

    67, (h) a variable light domain region comprising the amino acid sequence of SEQ ID NO;

    71, (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;

    75, (j) a variable light domain region comprising the amino acid sequence of SEQ ID NO;

    79;

    (k) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;

    94;

    (l) a variable light domain region comprising the amino acid sequence of SEQ ID NO;

    98;

    (m) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;

    43 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;

    47, (n) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;

    51 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;

    55, (o) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;

    59 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;

    63, (p) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;

    67 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;

    71, (q) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;

    75 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;

    79, (r) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO;

    94 and a variable light domain region comprising the amino acid sequence of SEQ ID NO;

    98, (s) a variable heavy chain a comprising complementarity determining region (CDR)1comprising the amino acid sequence of SEQ ID NO;

    44, a CDR2 comprising the amino acid sequence of SEQ ID NO;

    45, and a CDR3 comprising the amino acid sequence of SEQ ID NO;

    46 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    48, a CDR2 comprising the amino acid sequence of SEQ ID NO;

    49, and a CDR3 comprising the amino acid sequence of SEQ ID NO;

    50, (t) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    52, a CDR2 comprising the amino acid sequence of SEQ ID NO;

    53, and a CDR3 comprising the amino acid sequence of SEQ ID NO;

    54 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    56, a CDR2 comprising the amino acid sequence of SEQ ID NO;

    57, and a CDR3 comprising the amino acid sequence of SEQ ID NO;

    58, (u) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    60, a CDR2 comprising the amino acid sequence of SEQ ID NO;

    61, and a CDR3 comprising the amino acid sequence of SEQ ID NO;

    62 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    64, a CDR2 comprising the amino acid sequence of SEQ ID NO;

    65, and a CDR3 comprising the amino acid sequence of SEQ ID NO;

    66, (v) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    68, a CDR2 comprising the amino acid sequence of SEQ ID NO;

    69, and a CDR3 comprising the amino acid sequence of SEQ ID NO;

    70 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    72, a CDR2 comprising the amino acid sequence of SEQ ID NO;

    73, and a CDR3 comprising the amino acid sequence of SEQ ID NO;

    74, (w) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    76, a CDR2 comprising the amino acid sequence of SEQ ID NO;

    77, and a CDR3 comprising the amino acid sequence of SEQ ID NO;

    78 and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    80, a CDR2 comprising the amino acid sequence of SEQ ID NO;

    81, and a CDR3 comprising the amino acid sequence of SEQ ID NO;

    82, and (x) a variable heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    95, a CDR2 comprising the amino acid sequence of SEQ ID NO;

    96, and a CDR3 comprising the amino acid sequence of SEQ ID NO;

    97, and a variable light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    99, a CDR2 comprising the amino acid sequence of SEQ ID NO;

    100, and a CDR3 comprising the amino acid sequence of SEQ ID NO;

    101, wherein the antibody or antigen-binding fragment thereof specifically binds to Repulsive Guidance Molecule c (“

    RGMc”

    ).

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×